Karyopharm Therapeutics Inc. (KPTI)
NASDAQ: KPTI · Real-Time Price · USD
0.635
-0.015 (-2.25%)
Dec 20, 2024, 4:00 PM EST - Market closed
Karyopharm Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 148.44 | 146.03 | 157.07 | 209.82 | 108.09 | 40.89 | Upgrade
|
| Revenue Growth (YoY) | 1.77% | -7.03% | -25.14% | 94.12% | 164.31% | 34.80% | Upgrade
|
| Cost of Revenue | 16.72 | 4.94 | 5.21 | 3.4 | 2.71 | 124.75 | Upgrade
|
| Gross Profit | 131.72 | 141.09 | 151.86 | 206.42 | 105.38 | -83.85 | Upgrade
|
| Selling, General & Admin | 118.94 | 131.88 | 145.4 | 143.85 | 126.42 | 105.42 | Upgrade
|
| Research & Development | 138.75 | 138.75 | 148.66 | 160.84 | 150.81 | - | Upgrade
|
| Operating Expenses | 257.69 | 270.63 | 294.06 | 304.69 | 277.23 | 105.42 | Upgrade
|
| Operating Income | -125.97 | -129.54 | -142.2 | -98.27 | -171.85 | -189.28 | Upgrade
|
| Interest Expense | -32.43 | -23.82 | -25 | -26.05 | -27.14 | -15.65 | Upgrade
|
| Interest & Investment Income | 8.44 | 10.94 | 2.36 | 0.58 | 2.82 | 5.42 | Upgrade
|
| Other Non Operating Income (Expenses) | 18.07 | -0.36 | -0.08 | -0.09 | 0.21 | -0.05 | Upgrade
|
| Pretax Income | -87.18 | -142.78 | -164.92 | -123.82 | -195.96 | -199.55 | Upgrade
|
| Income Tax Expense | 0.3 | 0.32 | 0.37 | 0.27 | 0.31 | 0.04 | Upgrade
|
| Net Income | -87.48 | -143.1 | -165.29 | -124.09 | -196.27 | -199.59 | Upgrade
|
| Net Income to Common | -87.48 | -143.1 | -165.29 | -124.09 | -196.27 | -199.59 | Upgrade
|
| Shares Outstanding (Basic) | 119 | 114 | 82 | 75 | 72 | 62 | Upgrade
|
| Shares Outstanding (Diluted) | 119 | 114 | 82 | 75 | 72 | 62 | Upgrade
|
| Shares Change (YoY) | 10.23% | 39.51% | 8.84% | 4.41% | 16.28% | 9.11% | Upgrade
|
| EPS (Basic) | -0.73 | -1.25 | -2.02 | -1.65 | -2.72 | -3.22 | Upgrade
|
| EPS (Diluted) | -1.08 | -1.25 | -2.02 | -1.65 | -2.72 | -3.22 | Upgrade
|
| Free Cash Flow | -120.46 | -92.72 | -149.67 | -107.33 | -160.38 | -191.03 | Upgrade
|
| Free Cash Flow Per Share | -1.01 | -0.81 | -1.83 | -1.43 | -2.23 | -3.08 | Upgrade
|
| Gross Margin | 88.73% | 96.62% | 96.68% | 98.38% | 97.50% | -205.06% | Upgrade
|
| Operating Margin | -84.86% | -88.71% | -90.53% | -46.84% | -159.00% | -462.85% | Upgrade
|
| Profit Margin | -58.93% | -97.99% | -105.23% | -59.14% | -181.59% | -488.08% | Upgrade
|
| Free Cash Flow Margin | -81.15% | -63.49% | -95.29% | -51.15% | -148.38% | -467.14% | Upgrade
|
| EBITDA | -125.63 | -129.01 | -141.58 | -97.48 | -170.88 | -188.3 | Upgrade
|
| EBITDA Margin | -84.64% | -88.34% | -90.14% | -46.46% | -158.10% | - | Upgrade
|
| D&A For EBITDA | 0.34 | 0.53 | 0.62 | 0.79 | 0.97 | 0.97 | Upgrade
|
| EBIT | -125.97 | -129.54 | -142.2 | -98.27 | -171.85 | -189.28 | Upgrade
|
| EBIT Margin | -84.86% | -88.71% | -90.53% | -46.84% | -159.00% | - | Upgrade
|
| Revenue as Reported | 148.44 | 146.03 | 157.07 | 209.82 | 108.09 | 40.89 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.